Research programme: angiogenesis inhibitors - XOMA

Drug Profile

Research programme: angiogenesis inhibitors - XOMA

Alternative Names: BPI-derived compounds research programme - XOMA; Research programme: BPI-derived compounds - XOMA; Research programme: heparin neutralisers - XOMA; Research programme: retinal disorders - XOMA; Retinal disorders research programme - XOMA; XMP 300

Latest Information Update: 14 Jun 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XOMA
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer metastases; Inflammation; Retinal disorders

Most Recent Events

  • 14 Jun 2006 No development reported - Preclinical for Retinal disorders in USA (unspecified route)
  • 20 Oct 2003 The BPI-derived compounds research programme is available for licensing for Retinal Disorders (http://www.xoma.com)
  • 20 Oct 2003 No development reported - Preclinical for Cancer metastases in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top